Exzolt is a drug owned by INTERVET, INC. It is protected by 8 US drug patents filed from 2027 to 2036. All patents are active. Details of Exzolt’s patents and their expiration are given below.
| Drug Patent Number | Drug Patent Expiry | Status |
|---|---|---|
 | ||
| US12128032 | 02 Mar, 2035 | Active |
| US10653675 | 19 Dec, 2034 | Active |
| US11304934 | 19 Dec, 2034 | Active |
| US11883530 | 19 Dec, 2034 | Active |
| US10272071 | 19 Dec, 2034 | Active |
| US7622972 | 28 Jun, 2027 | Active |
Exclusivity Information
Exzolt holds 1 exclusivity out of which 0 have expired. Its last outstanding exclusivity is set to expire in 2028. Details of Exzolt's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| NCI | Jul 17, 2028 |
About Exzolt
Exzolt is a drug
owned by INTERVET, INC.
Exzolt uses
Fluralaner as the active
ingredient.
Active Ingredient:
Exzolt uses
Fluralaner as the active ingredient.
Check out other Drugs and Companies using
Fluralaner ingredient.